NCAPD3 has been identified as a new biomarker for prostate cancer [13], and we have endorsed this claim based on our previous report that NCAPD3 acted as an androgen/androgen receptor (AR) axis-targeted gene to upregulated lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) for accelerating prostate cancer progression through STAT3 [14, 15]. The gene discussed is STAT3; the disease is prostate carcinoma.